Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Innovent Biologics, SanegeneBio Partner on siRNA Hypertension Drug | Contract Pharma
Breaking News, Collaborations & Alliances

Innovent Biologics, SanegeneBio Partner on siRNA Hypertension Drug

Innovent obtains exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908.

Innovent Biologics, a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and SanegeneBio have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for the treatment of hypertension. Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908.
 
SGB-3908 is an IND-enabling stage siRNA drug developed based on SanegeneBio’s LEAD (Ligand and Enhancer Assisted Delivery) platform. Both parties will be jointly responsible for the development of SGB-3908 to certain stage. Innovent has an exclusive option to obtain the exclusive development, manufacturing, and commercialization license of SGB-3908 in different areas worldwide. After Innovent exercises its option, SanegeneBio will be eligible to receive subsequent milestone payments, as well as royalties on sales.
 
The alliance combines SanegeneBio’s RNA technology and Innovent’s clinical development experience and commercialization capability to help accelerate development and commercial success.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters